Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy.
Weber
M
M
Department of Surgery, University of Pennsylvania, Medical Center, Philadelphia, USA.
Deng
S
S
Arenas
J
J
Aradhye
S
S
Grossman
R
R
Shaw
L
L
Naji
A
A
Barker
C
C
Brayman
K L
KL
D001741:Black or African American; D001379:Azathioprine / Q000627:therapeutic use; D044383:Black People; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015143:Philadelphia; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*; D014019:Tissue Donors; D044465:White People
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D016559:Tacrolimus